Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
Vera Ignjatović, Founder and Managing Director at Ignis Innovations Pty Ltd, Principal Consultant of Translational Research at Johns Hopkins All Children’s Hospital, shared on LinkedIn about a recent article she and her colleagues co-authored, published in JTH, adding:
“Children with blood clots deserve better, and that starts with drugs actually designed and tested for them.
The truth is, most antithrombotic drugs children receive today were developed for adults.
Heparins and warfarin have been the backbone of treatment for over half a century, with a wave of newer agents opening new possibilities.
The critical question is: how do we rigorously study these drugs in children to understand their true benefits and risks?
Our new guidance paper provides expert guidance on exactly that – the rigorous study of antithrombotic drugs, from trial design and endpoint selection to regulatory strategy and real-world effectiveness.
Behind this work is a growing international community (Pedi-ATLAS and the ISTH Pediatric/Neonatal SSC) committed to ensuring that pediatric patients never simply an afterthought in drug development.
Because children are Not small adults.
They deserve science built for them!
‘Development of New Antithrombotic Drugs for Children (Part ), guidance from the International Society on Thrombosis and Haemostasis (ISTH) Scientific Standardization Committee Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group’ ”
Title: Development of new antithrombotic drugs for children (part ): guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group
Authors: Neil A. Goldenberg, Scott D. Berkowitz, Marisol Betensky, Susanne Holzhauer, Vera Ignjatovic, Amy Kiskaddon, Daniel Schaufelberger, Paul Monagle, Christoph Male
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026
-
Jul 16, 2026, 18:40Sara Buonomo: Predicting Relapse in Immune-Mediated TTP at ISTH 2026